Pilot Funding Announcement for Tumor Immunology and Immunotherapy

Posted in Announcement  |  Tagged

The Georgetown Lombardi Comprehensive Cancer Center (LCCC), as part of its Cancer Immunotherapy Initiative, announces the availability of Tumor Immunology/Immunotherapy Pilot Funds based here at LCCC. These Awards are made available through the generous gift of Stan and Linda Sher and are called “Sher Grants.”

This Award is anticipated to provide support for two different categories of investigators:

  1. Junior faculty within the Cancer Center (within 5 years of completion of training) to assist them in transitioning from training to an independent career as either a laboratory scientist focused on tumor immunology or a physician scientist focused on cancer immunotherapy.
  2. Established scientists attempting to transition components of their research toward exploring the potential impact on, or contributions of, the immune system.

Awards for junior faculty will be selected based on several factors including:

  1. Quality of the scientific proposal (40%)
  2. Potential impact on cancer immunotherapy (20%)
  3. Quality and potential of the applicant for establishing an independent career (20%)
  4. Quality of the mentor and research environment (20%)

Awards for established investigators will be selected based on:

  1. Quality of the scientific proposal (60%)
  2. Potential impact on cancer immunotherapy (40%)

Potential topics for pilot funding include:

  • Integrating immunotherapy with targeted therapy, radiation and surgery
  • Identifying mechanisms of resistance to immunotherapy
  • Predictive biomarker studies of response or toxicity – including imaging, blood based and tumor based
  • Adoptive cellular therapy projects
  • Study of the role of host polymorphisms and the microbiome in response to therapy
  • Creation of immune competent preclinical models for testing immunotherapy
  • Identifying targetable mechanisms of T cell exclusion
  • Quality of Life or Health Services Research focused on establishing the relative value of Immunotherapy
  • Survivorship issues with Immunotherapy

Studies that utilize either the Perkin Elmer Vectra Quantitative Immunofluorescence Platform, or the Nanostring RNA or NextSeq platforms in GESR are particularly welcome. Applicants may be members of the faculty at either Georgetown University Medical Center, other Departments within Georgetown University, MedStar Health, or the John Theurer Cancer Center.

Grants will be competitively awarded with up to 4 grants of up to $50,000/year provided. Specific Aims for 1 year’s work should be provided together with a 5-page research plan. Applications are due Monday January 29th, 2018.

Application Forms

Please contact Sharon Levy (SGL5@Georgetown.edu (new window)) to notify her of your intent to submit an application and she will send you a template application. The deadline for receipt of completed applications by Sharon Levy (SGL5@Georgetown.edu) is Monday, January 29th, 2018. Note that all applications must be submitted electronically as a single, low-resolution PDF file. Incomplete and non-electronic applications will be returned without scientific review. The Sher Research Grant Committee will award grants in March 2018 following peer review.

Questions and requests for additional information should be directed to Sharon Levy (SGL5@Georgetown.edu (new window)).